nach oben

Die Onkologie

Erschienen in:

01.02.2007 | Leitthema

Neck-Dissection nach Radiochemotherapie bei Kopf-Hals-Karzinomen

verfasst von: Prof. Dr. A.A. Duenne, P.J. Barth, V. Budach, J.A. Werner

Erschienen in: Die Onkologie | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei Patienten mit Karzinomen der oberen Luft- und Speisewege ist der Nachweis manifester lymphogener Metastasen der wichtigste prognostische Faktor für das Gesamtüberleben. Das Überleben reduziert sich mit der Anzahl regionärer Lymphknotenmetastasen signifikant. Daher gehört die Behandlung des regionären Lymphabflusses (Neck-Dissection) bei einem primär chirurgischen Vorgehen zu den Therapieoptionen. Bei multimodalen Therapiekonzepten gilt dies auch für die primäre Radiochemotherapie. Diverse Probleme kommen durch die in der Literatur erläuterten Daten zutage: Alle Studien verwenden unterschiedliche Radiochemotherapieprotokolle und unterschiedliche Zeitspannen zwischen primärer Radiochemotherapie und Neck-Dissection. Die Indikation zur Neck-Dissection bleibt unklar. Ebenfalls unklar ist die Indikation zum Ausmaß der Neck-Dissection. Die publizierten Daten vermitteln unvollständige bis fehlende Angaben im Hinblick auf N-Status, Tumorlokalisation und Stadienverteilung etc. Ebenfalls unvollständig bis fehlend sind Angaben bezüglich der Korrelation zwischen prä- und postoperativem Halsstatus sowie der Bild gebenden Diagnostik und der postoperativ histologisch verifizierten Ergebnisse. Auch im Hinblick auf die histopathologische Begutachtung fehlen Standards. Die Frage, ab wann eine bestrahlte Zelle nicht apoptotisch oder nekrotisch, sondern noch zu weiterer Proliferation und Metastasierung fähig ist, wird nicht klar beantwortet.

Schuller DE, McGuirt WF, McCabe BJ et al. (1980) The prognostic significance of metastastic cervical lymph nodes. Laryngoscope 90: 557–570PubMed

Snow GB, Annyas AA, van Slooten EA et al. (1982) Prognostic factors of neck node metastasis. Clin Otolaryngol 7: 185–192PubMed

McLaughlin MP, Mendenhall WM, Mancuso AA et al. (1995) Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. Head Neck 17: 190–198PubMed

Nibu KI, Yanagisawa A, Nakamizo M et al. (1998) Clinical role of p53 and p21WAF1/CIP1 in squamous cell carcinoma of the pyriform sinus. Acta Otolaryngol 118: 432–437CrossRefPubMed

Snyderman NL, Johnson JT, Schramm VL Jr et al. (1985) Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer 56: 1597–1599CrossRefPubMed

Myers JN, Greenberg JS, Mo V et al. (2001) Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 92: 3030–3036CrossRefPubMed

Wenzel S, Sagowski C, Kehrl W et al. (2004) The prognostic impact of metastatic pattern of lymph nodes in patients with oral and oropharyngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol 261: 270–275CrossRefPubMed

Wiegand S, Dunne AA, Muller HH et al. (2005) Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 104: 94–100CrossRefPubMed

Barkley HT Jr, Fletcher GH, Jesse RH et al. (1972) Management of cervical lymph node metastases in squamous cell carcinomas of the tonsillar fossa, base of tongue, supraglottic larynx, and Hypopharynx. Am J Surg 124: 462–467CrossRefPubMed

10.

Jones AS, Beasley NJP, Houghton DJ et al. (1998) Treatment of oropharyngeal carcinoma by irradiation or by surgery. Clin Otolaryngol 23: 172–176CrossRefPubMed

11.

Wong RJ, Rinaldo A, Ferlito A et al. (2002) Occult Cervical Metastasis in Head and Neck Cancer and its Impact on Therapy. Acta Otolaryngol 122: 107–114PubMed

12.

Wolf GT, Forastiere A, Ang K (1999) Workshop report: organ prservation strategies in advanced head and neck cancer/current status and future directions. Head Neck 21: 689–693CrossRefPubMed

13.

Lavertu P, Adelstein DJ, Saxton JP (1999) Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: An 8-year single-institution experience. Arch Otolaryngol Head Neck Surg 125: 142–148PubMed

14.

O’Sullivan B, Warde P, Grice B (2001) The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 51: 332–343PubMed

15.

Poulsen MG, Denham JW, Peters LJ (2001) A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Onco1 60: 113–122CrossRef

16.

Fallai C, Olmi P, Cellai E (1993) Advanced carcinomas of the oropharynx treated with radiotherapy –a comparison of three different fractionation Schemes. Am J Otolaryngol 14: 31–37CrossRefPubMed

17.

Puthawala A, Nisar Syed AM, Gamie S et al. (2001) Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. Int J Radiat Oncol Biol Phys 51: 354–362CrossRefPubMed

18.

Hosal AS, Carrau RL, Johnson JT et al. (2000) Selective neck dissection in the management of the clinically node-negative neck. Laryngoscope 110: 2037–2040CrossRefPubMed

19.

Van den Brekel MW, van der Waal I, Meijer CJ et al. (1996) The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections. Laryngoscope 106: 987–991CrossRefPubMed

20.

Sumi M, Ohki M, Nakamura T (2001) Comparison of Sonography and CT for differentiating benign from malignant cervical lymph nodes in patients with squamous cell carcinoma of the head and neck. Am J.Radiol 178: 1019–1024

21.

Van den Brekel MW, Castelijns JA, Stel HV et al. (1993) Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol 250: 11–17PubMed

22.

Mabanta SR, Mendenhall WM, Stringer SP et al. (1999) Salvage treatment for neck recurnce after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck 21: 591–594CrossRefPubMed

23.

Wong RJ, Lin DT, Schoder H et al. (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20: 4199–4208CrossRefPubMed

24.

Ware RE, Matthews JP, Hicks RJ et al. (2004) Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 26: 1008–1017CrossRefPubMed

25.

Kubota K, Yokoyama J, Yamaguchi K et al. (2004) FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 31: 590–595CrossRefPubMed

26.

Porceddu SV, Jarmolowski E, Hicks RJ et al. (2005) Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27: 175–181CrossRefPubMed

27.

Lowe VJ, Dunphy FR, Varvares M et al. (1997) Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 19: 666–674CrossRefPubMed

28.

Rogers JW, Greven KM, McGuirt WF et al. (2004) Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys 58: 694–697CrossRefPubMed

29.

Boysen M, Lovdal O, Natvig K et al. (1992) Combined radiotherapy and surgery in the treatment of neck node metastases from squamous cell carcinoma of the head and neck. Acta Oncol 31: 455–460PubMed

30.

Peters LJ, Weber RS, Morrison WH et al. (1996) Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. Head Neck 18: 552–559CrossRefPubMed

31.

Mendenhall WM, Million RR, Cassisi NJ (1986) Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. Int J Radiat Oncol Biol Phys 12: 733–740PubMed

32.

Mendenhall WM, Parsons JT, Amdur RJ et al. (1988) Squamous cell carcinoma of the head and neck treated with radiotherapy: does planned neck dissection reduce the change for successful surgical management of subsequent local recurrence? Head Neck Surg 10: 302–304PubMed

33.

Armstrong J, Pfister D, Strong E (1993) et al. The management of the clinically positive neck as part of a larynx preservation approach. Int J Radiat Oncol Biol Phys 26: 759–765PubMed

34.

Koch WM, Lee DJ, Eisele DW et al. (1995) Chemoradiotherapy for organ preservation in oral and pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 121: 974–980PubMed

35.

Garden AS, Glisson BS, Ang KK et al. (1999) Phase I/II trial of radiation with chemotherapy „boost“ for advanced squamous cell carcinomas of the head and neck: toxicities and responses. J Clin Oncol 17: 2390–2395PubMed

36.

Robbins KT, Wong FS, Kumar P et al. (1999) Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 125: 670–675PubMed

37.

Stenson KM, Haraf DJ, Pelzer H et al. (2000) The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 126: 950–956PubMed

38.

Wanebo H, Chougule P, Ready N et al. (2001) Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol 8: 644–650CrossRefPubMed

39.

Grabenbauer GG, Rodel C, Ernst-Stecken A et al. (2003) Neck dissection following radiochemotherapy of advanced head and neck cancer--for selected cases only? Radiother Oncol 66: 57–63CrossRefPubMed

40.

McHam SA, Adelstein DJ, Rybicki LA et al. (2003) Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck 25: 791–798CrossRefPubMed

41.

Argiris A, Stenson KM, Brockstein BE et al. (2004) Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 26: 447–455CrossRefPubMed

42.

Brizel DM, Prosnitz RG, Hunter S et al. (2004) Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58: 1418–1423CrossRefPubMed

43.

Sapundzhiev NR, Barth P, Engenhart-Cabillic R et al. (2004) Effectiveness of radiochemotherapy on lymph node metastases in patients with advanced oropharyngeal cancer. Oral Oncol 40: 1007–1016CrossRefPubMed

44.

Otto KJ, Johnstone PAS, Chen A (2006) Salvage neck dissection in the era of combined treatment techniques for head and neck cancer. Arch Otolaryngol Head Neck Surg 132: 906–907CrossRef

45.

Robbins KT, Shannon K (2006) Superselective neck dissection following chemoradiation: feasibility based on clinical and pathological comparisons. Arch Otolaryngol Head Neck Surg 132: 841CrossRef

46.

Nayak JV, Daamen N, Ferris RL et al. (2006) Deferring planned neck dissection after chemoradiation therapy in stage IV head and neck cancer: the utility of PET/CT. Arch Otolaryngol Head Neck Surg 132: 843CrossRef

47.

Pellitteri PK, Ferlito A, Rinaldo A et al. (2006) Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all? Head Neck 28: 166–175CrossRefPubMed

Titel: Neck-Dissection nach Radiochemotherapie bei Kopf-Hals-Karzinomen
verfasst von: Prof. Dr. A.A. Duenne
P.J. Barth
V. Budach
J.A. Werner
Publikationsdatum: 01.02.2007
Verlag: Springer-Verlag
Erschienen in: Die Onkologie / Ausgabe 2/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-006-1168-6

Springer Medizin

Neck-Dissection nach Radiochemotherapie bei Kopf-Hals-Karzinomen

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Orale Mukositis

Plattform für den wissenschaftlichen Austausch

Photodynamische Therapie

Neue Entwicklungen in der Onkologie bei Kopf-Hals-Karzinomen

Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome

Medikamentöse Systemtherapie bei rezidivierten oder metastasierten Kopf-Hals-Karzinomen

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie